ProKidney Corp. (PROK) stock
Close on Nov 11, 2026Market cap $341.63MP/E –Yield –
ProKidney Corp. grew revenue 55.2% to $818.00K over the twelve months to Jun 30, 2026. Free cash flow was -$159.73M. At the latest close the market valued the company at $341.63M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $341.63M
- P/E ratio
- –
- Price to sales
- 417.63
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -46.76%
Fundamentals
- Revenue
- $818.00K
- Net income
- -$84.16M
- Free cash flow
- -$159.73M
Trading
- Next earnings
- Mar 17, 2027 (estimated, during market hours)
- Previous close
- $1.11
- Open
- $1.15
- Day's range
- $1.11 – $1.18
- Volume
- 595,865
- Average volume (20 days)
- 1,406,662
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.32
- 52-week range
- $0.87 – $2.88
- RSI (14 days)
- 36.5
- Volatility (1 year)
- 74.4%
- Relative volume
- 0.45×
- WACC
- 11.5%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PROK | S&P 500 | Difference | PROK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -35.1% | -2.4% | −32.6 pts | ||
| 3 months | -29.8% | -1.2% | −28.7 pts | ||
| Year to date | -49.6% | +12.3% | −61.8 pts | ||
| 1 year | -59.6% | +12.4% | −72.1 pts | ||
| 3 years | -29.4% | +78.8% | −108.2 pts | -10.9% | +21.4% |
| 5 years | -88.6% | +75.2% | −163.8 pts | -35.3% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ProKidney filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About ProKidney
Biological Products, (No Diagnostic Substances)
ProKidney Corp. is a clinical-stage biotechnology company that develops autologous cell therapies to preserve kidney function in individuals suffering from chronic kidney disease and diabetes. Its lead product candidate, rilparencel, uses selected renal cells harvested from a patient's own kidney biopsy, which are processed and reinjected into the damaged organ through a minimally invasive procedure. Operating in a single segment, the company focuses on creating personalized regenerative treatments that eliminate the need for donor immunosuppression. Its end users are patients with advanced chronic kidney disease and diabetes.
Company profile, executives and historyProKidney stock: common questions
What is ProKidney's stock price?
PROK closed at $1.13 on Nov 11, 2026, up 1.80% on the day. Over the past 52 weeks it traded between $0.87 and $2.88.
What is ProKidney's market cap?
ProKidney was worth $341.63M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does ProKidney make?
ProKidney reported revenue of $818.00K for the twelve months to Jun 30, 2026, up 55.2% from a year earlier.
Does ProKidney pay a dividend?
No. ProKidney has not paid a cash dividend over the last twelve months.
When does ProKidney report earnings next?
ProKidney is expected to report Q4 FY2026 results on Mar 17, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has PROK stock performed over the past year?
Including dividends, PROK returned -59.6% over the past year, against +12.4% for the S&P 500.
How many PROK shares are sold short?
24M shares were sold short at the latest FINRA report, 21.70% of the float, or 22.5 days of average trading volume.
Who are ProKidney's competitors?
Companies most similar to ProKidney by business, industry and size include PLUR, SABS, LGVN, IMA, SCNI.
See a number that looks wrong?